E71.521 Adolescent X-linked adrenoleukodystrophy

Name of the Condition

• Adolescent X-linked adrenoleukodystrophy

Summary

Adolescent X-linked adrenoleukodystrophy is a genetic disorder that affects the nervous system and adrenal glands during adolescence. It results from the accumulation of very long-chain fatty acids (VLCFAs), leading to damage to the myelin sheath around nerve cells and adrenal insufficiency.

Causes

This condition is caused by mutations in the ABCD1 gene on the X chromosome. The mutation disrupts the breakdown of VLCFAs, causing them to accumulate in tissues and damage the adrenal glands and nervous system.

Risk Factors

• Being male, as the condition is X-linked.
• Family history of X-ALD due to its hereditary nature.

Symptoms

• Progressive neurological deterioration.
• Adrenal insufficiency (Addison's disease).
• Behavioral changes, weakness, and spasticity.
• In severe cases, loss of vision, hearing, and mobility.

Diagnosis

Diagnosis involves blood tests to measure VLCFA levels, genetic testing to identify ABCD1 gene mutations, and MRI scans to detect changes in brain structures.

Treatment Options

• Corticosteroid replacement therapy: For adrenal insufficiency.
• Lorenzo's oil: To help normalize VLCFA levels, although effectiveness varies.
• Hematopoietic stem cell transplantation (HSCT): Stops disease progression in cerebral ALD if performed early.

Prognosis and Follow-Up

Prognosis varies depending on the severity of neurological involvement and timing of treatment. Regular follow-up includes monitoring adrenal function, neurological status, and VLCFA levels to manage symptoms and complications.

Complications

• Progressive neurological decline.
• Adrenal crisis due to untreated adrenal insufficiency.
• Loss of motor and sensory function.

Lifestyle & Prevention

• Maintain regular medical monitoring for early detection of adrenal or neurological changes.
• Adhere to prescribed therapies to manage VLCFA levels and adrenal function.

When to Seek Professional Help

Seek immediate medical attention for symptoms of adrenal insufficiency (e.g., fatigue, low blood pressure) or rapid neurological decline (e.g., weakness, behavioral changes).

Tips for Medical Coders

Document the age of onset (adolescent) and clinical presentation to support the specificity of E71.521. Include details on VLCFA testing, genetic confirmation, and neurological imaging when available. Ensure documentation aligns with the adolescent onset and X-linked inheritance pattern.